Independent Risk Factors Analysis and Model Construction For Recurrence After Radiofrequency/Microwave Ablation of Colorectal Cancer With Liver Metastases: a Retrospective, Multicenter Trial

The Central Hospital of Lishui City0 sites80 target enrollmentMarch 12, 2022

ConditionsColorectal Cancer With Liver Metastases

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Colorectal Cancer With Liver Metastases
Sponsor: The Central Hospital of Lishui City
Enrollment: 80
Primary Endpoint: The first recurrence of colorectal cancer with liver metastasis (CRLM) after radiofrequency/microwave ablation, assessed up to 18 months
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

This study is a retrospective, multicenter clinical study. The main objective is to analyze the risk factors affecting the recurrence of colorectal cancer patients with liver metastases who received radiofrequency/microwave ablation. Finally, we will construct a recurrence risk prediction model based on the risk factors and validated the model.

Registry

clinicaltrials.gov

Start Date

March 12, 2022

End Date

August 12, 2022

Last Updated

4 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

The Central Hospital of Lishui City

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Age：older than 18 years；
•Patients with a single tumor diameter ≤5cm, no more than 3 tumor nodules, and the largest tumor diameter ≤3cm；
•Absence of vessel, bile duct and adjacent organ invasion and distant metastasis;
•The primary tumor of colorectal cancer has been resected, the liver metastases cannot be resected or the patient is unwilling to undergo surgery (clinical or pathological confirmation);
•Normal coagulation status and liver function child-pugh A or B;
•Liver metastases have not received other antitumor therapy after radiofrequency/microwave therapy (before disease progression);
•Routine laboratory tests were performed before the first RF/microwave treatment;
•Follow up for more than 12 months;
•Obtained free informed consent.

Exclusion Criteria

•Large tumor, or diffuse intrahepatic metastasis;
•Accompanied by vascular tumor thrombus or invasion of adjacent organs;
•The primary tumor of colorectal cancer has not been resected, with extrahepatic metastasis;
•Uncorrectable coagulation dysfunction and severe blood abnormalities, those with severe bleeding tendency;
•Intractable massive ascites, cachexia;
•Active infection, especially inflammation of the biliary system;
•Severe liver, kidney, heart, lung, brain and other major organ failure;
•Patients with impaired consciousness or unable to cooperate with treatment;
•Missing follow-up data.

Outcomes

Primary Outcomes

The first recurrence of colorectal cancer with liver metastasis (CRLM) after radiofrequency/microwave ablation, assessed up to 18 months

Time Frame: Time from enrollment to disease recurrence, assessed up to 18 months

The first recurrence of colorectal cancer with liver metastasis (CRLM) after radiofrequency/microwave ablation, assessed up to 18 months

Secondary Outcomes

Patients with colorectal cancer with liver metastases (CRLM) developed new metastases after radiofrequency/microwave ablation,assessed up to 18 months(Time from enrollment to developed new metastases, assessed up to 18 months)